AG
PSTX

Algert Global’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Algert Global’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19,410
Closed -$185K – 552
2021
Q1 		$185K Buy
+19,410
New +$190K 0.06% 383

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's PSTX Position: Q2 2021 in Review

Algert Global sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2021, closing a stake of 19,410 shares — an estimated $185K sold.

Algert Global first reported a position in PSTX in Q1 2021 and held it in 1 quarter. The position peaked at $185K in Q1 2021. 71 funds tracked by Wall St. Rank hold PSTX as of Q2 2021.

  • Algert Global reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Algert Global sold 19,410 Poseida Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $185K.
  • Algert Global first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Algert Global's Poseida Therapeutics, Inc. Common Stock position peaked at $185K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Algert Global's 13F filing for Q2 2021, filed 13 Aug 2021.